News stories about DarioHealth Corp. (NASDAQ:DRIO) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DarioHealth Corp. earned a news impact score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.5041565241357 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

DarioHealth Corp. (NASDAQ DRIO) opened at 2.00 on Monday. DarioHealth Corp. has a 1-year low of $1.81 and a 1-year high of $4.70. The company’s market cap is $19.16 million. The company’s 50 day moving average is $2.49 and its 200 day moving average is $2.99.

DarioHealth Corp. (NASDAQ:DRIO) last issued its earnings results on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.13. The firm had revenue of $1.21 million during the quarter. DarioHealth Corp. had a negative net margin of 206.95% and a negative return on equity of 626.32%. Equities research analysts forecast that DarioHealth Corp. will post ($0.41) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at

DarioHealth Corp. Company Profile

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

Receive News & Stock Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related stocks with our FREE daily email newsletter.